Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Quantitative Translation of Microfluidic Transporter in Vitro Data to in Vivo Reveals Impaired Albumin-Facilitated Indoxyl Sulfate Secretion in Chronic Kidney Disease.

van der Made TK, Fedecostante M, Scotcher D, Rostami-Hodjegan A, Sastre Toraño J, Middel I, Koster AS, Gerritsen KG, Jankowski V, Jankowski J, Hoenderop JGJ, Masereeuw R, Galetin A.

Mol Pharm. 2019 Sep 27. doi: 10.1021/acs.molpharmaceut.9b00681. [Epub ahead of print]

PMID:
31525064
2.

A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents.

Ogungbenro K, Wagner JB, Abdel-Rahman S, Leeder JS, Galetin A.

Eur J Clin Pharmacol. 2019 Sep;75(9):1227-1235. doi: 10.1007/s00228-019-02697-y. Epub 2019 Jun 6.

3.

Single-Incision Laparoscopic versus Open Sigmoidectomy for Diverticular Disease: A Disease-Stratified Matched-Pair Analysis.

Galetin A, Rink AD, Vestweber B, Vestweber KH, Galetin T.

Dig Surg. 2019 Mar 28:1-9. doi: 10.1159/000497449. [Epub ahead of print]

PMID:
30921802
4.

Hepatic Organic Anion Transporting Polypeptide-Mediated Clearance in the Beagle Dog: Assessing In Vitro-In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance.

Matsunaga N, Ufuk A, Morse BL, Bedwell DW, Bao J, Mohutsky MA, Hillgren KM, Hall SD, Houston JB, Galetin A.

Drug Metab Dispos. 2019 Mar;47(3):215-226. doi: 10.1124/dmd.118.084194. Epub 2018 Dec 28.

PMID:
30593544
5.

Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance.

Matsuzaki T, Scotcher D, Darwich AS, Galetin A, Rostami-Hodjegan A.

J Pharmacol Exp Ther. 2019 Feb;368(2):157-168. doi: 10.1124/jpet.118.251413. Epub 2018 Nov 9. Erratum in: J Pharmacol Exp Ther. 2019 Mar;368(3):474.

PMID:
30413628
6.

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium.

Chu X, Liao M, Shen H, Yoshida K, Zur AA, Arya V, Galetin A, Giacomini KM, Hanna I, Kusuhara H, Lai Y, Rodrigues D, Sugiyama Y, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):836-864. doi: 10.1002/cpt.1216. Review.

PMID:
30347454
7.

Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I.

Barnett S, Ogungbenro K, Ménochet K, Shen H, Humphreys WG, Galetin A.

J Pharmacol Exp Ther. 2019 Jan;368(1):125-135. doi: 10.1124/jpet.118.253062. Epub 2018 Oct 12.

PMID:
30314992
8.

Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition.

Chu X, Galetin A, Zamek-Gliszczynski MJ, Zhang L, Tweedie DJ; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):788-792. doi: 10.1002/cpt.1213. Epub 2018 Sep 21. No abstract available.

PMID:
30238965
9.

The International Transporter Consortium: Summarizing Advances in the Role of Transporters in Drug Development.

Giacomini KM, Galetin A, Huang SM.

Clin Pharmacol Ther. 2018 Nov;104(5):766-771. doi: 10.1002/cpt.1224. No abstract available.

PMID:
30137696
10.

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates.

Tan ML, Zhao P, Zhang L, Ho YF, Varma MVS, Neuhoff S, Nolin TD, Galetin A, Huang SM.

Clin Pharmacol Ther. 2019 Mar;105(3):719-729. doi: 10.1002/cpt.1205. Epub 2018 Oct 26.

PMID:
30074626
11.

Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.

Guo Y, Chu X, Parrott NJ, Brouwer KLR, Hsu V, Nagar S, Matsson P, Sharma P, Snoeys J, Sugiyama Y, Tatosian D, Unadkat JD, Huang SM, Galetin A; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):865-889. doi: 10.1002/cpt.1183. Epub 2018 Sep 12.

PMID:
30059145
12.

ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision.

Zamek-Gliszczynski MJ, Chu X, Cook JA, Custodio JM, Galetin A, Giacomini KM, Lee CA, Paine MF, Ray AS, Ware JA, Wittwer MB, Zhang L; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):781-784. doi: 10.1002/cpt.1082. Epub 2018 May 15.

PMID:
29761830
13.

Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro-In Vivo Scaling of Hepatic Uptake Clearance.

De Bruyn T, Ufuk A, Cantrill C, Kosa RE, Bi YA, Niosi M, Modi S, Rodrigues AD, Tremaine LM, Varma MVS, Galetin A, Houston JB.

Drug Metab Dispos. 2018 Jul;46(7):989-1000. doi: 10.1124/dmd.118.081315. Epub 2018 May 2.

PMID:
29720472
14.

Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium.

Yee SW, Brackman DJ, Ennis EA, Sugiyama Y, Kamdem LK, Blanchard R, Galetin A, Zhang L, Giacomini KM.

Clin Pharmacol Ther. 2018 Nov;104(5):803-817. doi: 10.1002/cpt.1098. Epub 2018 May 31. Review.

PMID:
29679469
15.

In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey.

Ufuk A, Kosa RE, Gao H, Bi YA, Modi S, Gates D, Rodrigues AD, Tremaine LM, Varma MVS, Houston JB, Galetin A.

J Pharmacol Exp Ther. 2018 Jun;365(3):688-699. doi: 10.1124/jpet.118.247767. Epub 2018 Apr 11.

PMID:
29643253
16.

Systematic review and comparison of national and international guidelines on diverticular disease.

Galetin T, Galetin A, Vestweber KH, Rink AD.

Int J Colorectal Dis. 2018 Mar;33(3):261-272. doi: 10.1007/s00384-017-2960-z. Epub 2018 Jan 18. Review.

PMID:
29349481
17.

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.

Barnett S, Ogungbenro K, Ménochet K, Shen H, Lai Y, Humphreys WG, Galetin A.

Clin Pharmacol Ther. 2018 Sep;104(3):564-574. doi: 10.1002/cpt.983. Epub 2018 Jan 17.

18.

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.

Tan ML, Yoshida K, Zhao P, Zhang L, Nolin TD, Piquette-Miller M, Galetin A, Huang SM.

Clin Pharmacol Ther. 2018 May;103(5):854-867. doi: 10.1002/cpt.807. Epub 2017 Oct 9.

19.

Incorporation of lysosomal sequestration in the mechanistic model for prediction of tissue distribution of basic drugs.

Assmus F, Houston JB, Galetin A.

Eur J Pharm Sci. 2017 Nov 15;109:419-430. doi: 10.1016/j.ejps.2017.08.014. Epub 2017 Aug 18.

PMID:
28823852
20.

In Vitro-In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug-Drug Interactions-Overview of Basic Prediction Methods.

Yoshida K, Zhao P, Zhang L, Abernethy DR, Rekić D, Reynolds KS, Galetin A, Huang SM.

J Pharm Sci. 2017 Sep;106(9):2209-2213. doi: 10.1016/j.xphs.2017.04.045. Epub 2017 Apr 26. Review.

PMID:
28456729
21.

Physiologically Based Pharmacokinetic Modeling of Drug Transporters to Facilitate Individualized Dose Prediction.

Galetin A, Zhao P, Huang SM.

J Pharm Sci. 2017 Sep;106(9):2204-2208. doi: 10.1016/j.xphs.2017.03.036. Epub 2017 Apr 5. Review.

PMID:
28390843
22.

Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance.

Scotcher D, Billington S, Brown J, Jones CR, Brown CDA, Rostami-Hodjegan A, Galetin A.

Drug Metab Dispos. 2017 May;45(5):556-568. doi: 10.1124/dmd.117.075242. Epub 2017 Mar 7.

23.

In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages.

Ufuk A, Assmus F, Francis L, Plumb J, Damian V, Gertz M, Houston JB, Galetin A.

Mol Pharm. 2017 Apr 3;14(4):1033-1046. doi: 10.1021/acs.molpharmaceut.6b00908. Epub 2017 Mar 20.

PMID:
28252969
24.
25.

Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.

Scotcher D, Jones CR, Galetin A, Rostami-Hodjegan A.

J Pharmacol Exp Ther. 2017 Mar;360(3):484-495. doi: 10.1124/jpet.116.237438. Epub 2017 Jan 5.

26.

Quantifying gut wall metabolism: methodology matters.

Hatley OJ, Jones CR, Galetin A, Rostami-Hodjegan A.

Biopharm Drug Dispos. 2017 Mar;38(2):155-160. doi: 10.1002/bdd.2062. Epub 2017 Feb 14. No abstract available.

27.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.

Margolskee A, Darwich AS, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Laplanche L, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:610-625. doi: 10.1016/j.ejps.2016.10.036. Epub 2016 Nov 2.

PMID:
27816631
28.

Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population.

Tsamandouras N, Guo Y, Wendling T, Hall S, Galetin A, Aarons L.

Pharmacogenet Genomics. 2017 Jan;27(1):27-38.

PMID:
27787353
29.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.

Darwich AS, Margolskee A, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:626-642. doi: 10.1016/j.ejps.2016.09.037. Epub 2016 Sep 28.

PMID:
27693299
30.

Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation.

Scotcher D, Jones C, Posada M, Galetin A, Rostami-Hodjegan A.

AAPS J. 2016 Sep;18(5):1082-1094. doi: 10.1208/s12248-016-9959-1. Epub 2016 Aug 9. Review.

PMID:
27506526
31.

Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data.

Scotcher D, Jones C, Posada M, Rostami-Hodjegan A, Galetin A.

AAPS J. 2016 Sep;18(5):1067-1081. doi: 10.1208/s12248-016-9942-x. Epub 2016 Jun 30. Review.

PMID:
27365096
32.

Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance.

Scotcher D, Jones C, Rostami-Hodjegan A, Galetin A.

Eur J Pharm Sci. 2016 Oct 30;94:59-71. doi: 10.1016/j.ejps.2016.03.018. Epub 2016 Mar 28.

33.

Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions.

Margolskee A, Darwich AS, Galetin A, Rostami-Hodjegan A, Aarons L.

AAPS J. 2016 Mar;18(2):321-32. doi: 10.1208/s12248-015-9849-y. Epub 2015 Dec 14.

34.

In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383.

Ufuk A, Somers G, Houston JB, Galetin A.

Pharm Res. 2015 Dec;32(12):3937-51. doi: 10.1007/s11095-015-1753-8. Epub 2015 Jul 30.

35.

Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.

Tsamandouras N, Wendling T, Rostami-Hodjegan A, Galetin A, Aarons L.

J Pharmacokinet Pharmacodyn. 2015 Aug;42(4):349-73. doi: 10.1007/s10928-015-9418-0. Epub 2015 May 26.

PMID:
26006250
36.

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.

Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2015 Apr;43(4):490-509. doi: 10.1124/dmd.114.062174. Epub 2015 Jan 13. Review.

PMID:
25587128
37.

Meta-analysis of expression of hepatic organic anion-transporting polypeptide (OATP) transporters in cellular systems relative to human liver tissue.

Badée J, Achour B, Rostami-Hodjegan A, Galetin A.

Drug Metab Dispos. 2015 Apr;43(4):424-32. doi: 10.1124/dmd.114.062034. Epub 2015 Jan 6.

PMID:
25564656
38.

Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach.

Tsamandouras N, Dickinson G, Guo Y, Hall S, Rostami-Hodjegan A, Galetin A, Aarons L.

Pharm Res. 2015 Jun;32(6):1864-83. doi: 10.1007/s11095-014-1581-2. Epub 2014 Dec 2.

PMID:
25446771
39.

ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays.

Lee CA, Kalvass JC, Galetin A, Zamek-Gliszczynski MJ.

Clin Pharmacol Ther. 2014 Sep;96(3):298-301. doi: 10.1038/clpt.2014.94.

PMID:
25141954
40.

Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestine.

Heikkinen AT, Friedlein A, Matondo M, Hatley OJ, Petsalo A, Juvonen R, Galetin A, Rostami-Hodjegan A, Aebersold R, Lamerz J, Dunkley T, Cutler P, Parrott N.

Pharm Res. 2015 Jan;32(1):74-90. doi: 10.1007/s11095-014-1446-8. Epub 2014 Jul 18.

PMID:
25033762
41.

Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs.

Nishimuta H, Houston JB, Galetin A.

Drug Metab Dispos. 2014 Sep;42(9):1522-31. doi: 10.1124/dmd.114.057372. Epub 2014 Jul 3.

PMID:
24994071
42.

Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.

Gertz M, Tsamandouras N, Säll C, Houston JB, Galetin A.

Pharm Res. 2014 Sep;31(9):2367-82. doi: 10.1007/s11095-014-1333-3. Epub 2014 Mar 13.

PMID:
24623479
43.

Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach.

Tsamandouras N, Dickinson G, Guo Y, Hall S, Rostami-Hodjegan A, Galetin A, Aarons L.

Clin Pharmacol Ther. 2014 Jul;96(1):90-100. doi: 10.1038/clpt.2014.55. Epub 2014 Mar 5.

PMID:
24598718
44.
45.

Understanding the transport properties of metabolites: case studies and considerations for drug development.

Zamek-Gliszczynski MJ, Chu X, Polli JW, Paine MF, Galetin A.

Drug Metab Dispos. 2014 Apr;42(4):650-64. doi: 10.1124/dmd.113.055558. Epub 2013 Dec 17. Review.

PMID:
24346835
46.

The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data.

Olivares-Morales A, Hatley OJ, Turner D, Galetin A, Aarons L, Rostami-Hodjegan A.

Pharm Res. 2014 Mar;31(3):720-30. doi: 10.1007/s11095-013-1193-2. Epub 2013 Sep 27.

47.

PBPK models for the prediction of in vivo performance of oral dosage forms.

Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, Jamei M, Lloyd R, Pepin X, Rostami-Hodjegan A, Sjögren E, Tannergren C, Turner DB, Wagner C, Weitschies W, Dressman J.

Eur J Pharm Sci. 2014 Jun 16;57:300-21. doi: 10.1016/j.ejps.2013.09.008. Epub 2013 Sep 21. Review.

PMID:
24060672
48.

Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.

Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM.

Clin Pharmacol Ther. 2014 Feb;95(2):189-98. doi: 10.1038/clpt.2013.187. Epub 2013 Sep 18.

PMID:
24048277
49.

Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, Matsson P, Moss A, Nagar S, Rosania GR, Bai JP, Polli JW, Sugiyama Y, Brouwer KL; International Transporter Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):126-41. doi: 10.1038/clpt.2013.78. Epub 2013 Apr 10. Review.

50.

ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, Nagar S, Pang KS, Korzekwa K, Swaan PW, Taub ME, Zhao P, Galetin A; International Transporter Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):64-79. doi: 10.1038/clpt.2013.45. Epub 2013 Feb 25. Review.

Supplemental Content

Loading ...
Support Center